| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Medard M Lec. [The diagnosis of hyperprolactinemia in clinical practice]. Ginekologia polska. vol 76. issue 12. 2006-07-17. PMID:16566383. |
neither the measurement of the serum prolactin level, nor dynamic tests with dopamine antagonists are able to determine the presence of macroprolactin molecules in the serum, and this can lead clinicians to establish the false diagnosis of hyperprolactinemia. |
2006-07-17 |
2023-08-12 |
Not clear |
| Cristina Cosi, Elisabeth Carilla-Durand, Marie Bernadette Assié, Anne Marie Ormiere, Mireille Maraval, Nathalie Leduc, Adrian Newman-Tancred. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. European journal of pharmacology. vol 535. issue 1-3. 2006-06-21. PMID:16554049. |
dopamine d2 receptor antagonists induce hyperprolactinemia depending on the extent of d2 receptor blockade. |
2006-06-21 |
2023-08-12 |
human |
| G Page-Wilson, P C Smith, C K Wel. Prolactin suppresses GnRH but not TSH secretion. Hormone research. vol 65. issue 1. 2006-03-02. PMID:16357488. |
to test the hypothesis that prolactin suppresses gnrh and tsh secretion in women, as preliminary evidence that a short-feedback dopamine loop also operates in the human, the effect of hyperprolactinemia on gnrh and tsh secretion was examined. |
2006-03-02 |
2023-08-12 |
human |
| Mary P Gillam, Hugo Fideleff, Hugo R Boquete, Mark E Molitc. Prolactin excess: treatment and toxicity. Pediatric endocrinology reviews : PER. vol 2 Suppl 1. 2006-02-27. PMID:16456489. |
dopamine agonists provide highly effective therapy for the treatment of hyperprolactinemia. |
2006-02-27 |
2023-08-12 |
Not clear |
| José M López, Eveline Oestreiche. Reversal of hypogonadotropic hypogonadism with tamoxifen in a patient with hyperprolactinemia resistant to dopamine agonists. Fertility and sterility. vol 84. issue 3. 2005-12-27. PMID:16169415. |
reversal of hypogonadotropic hypogonadism with tamoxifen in a patient with hyperprolactinemia resistant to dopamine agonists. |
2005-12-27 |
2023-08-12 |
Not clear |
| José M López, Eveline Oestreiche. Reversal of hypogonadotropic hypogonadism with tamoxifen in a patient with hyperprolactinemia resistant to dopamine agonists. Fertility and sterility. vol 84. issue 3. 2005-12-27. PMID:16169415. |
to determine the response to tamoxifen in a woman with hypogonadotropic hypogonadism induced by hyperprolactinemia resistant to dopamine agonist drugs. |
2005-12-27 |
2023-08-12 |
Not clear |
| Mark E Molitc. Medication-induced hyperprolactinemia. Mayo Clinic proceedings. vol 80. issue 8. 2005-08-23. PMID:16092584. |
if the patient's hyperprolactinemia is symptomatic, treatment strategies include switching to an alternative medication that does not cause hyperprolactinemia, using estrogen or testosterone replacement, or, rarely, cautiously adding a dopamine agonist. |
2005-08-23 |
2023-08-12 |
Not clear |
| M Aleem, J Choudhari, V Padwal, N Balasinor, P Parte, M K Gill-Sharm. Hyperprolactinemia affects spermiogenesis in adult male rats. Journal of endocrinological investigation. vol 28. issue 1. 2005-07-11. PMID:15816370. |
hyperprolactinemia is a known side effect of fluphenazine, a broad spectrum, long-acting phenothiazine known to be dopamine type-d2 receptor antagonist. |
2005-07-11 |
2023-08-12 |
rat |
| Shaun D Carstairs, Saralyn R William. Overdose of aripiprazole, a new type of antipsychotic. The Journal of emergency medicine. vol 28. issue 3. 2005-07-07. PMID:15769575. |
unlike other antipsychotics, it acts as a partial agonist at dopamine d(2) and 5-ht(1a) receptors, thereby mitigating most of the adverse reactions such as extrapyramidal side effects and hyperprolactinemia. |
2005-07-07 |
2023-08-12 |
Not clear |
| Oscar Gómez, José Antonio Bals. Implication of pituitary vasoactive intestinal peptide in dopaminergic inhibition of estrogen-induced pituitary hyperplasia and vascular endothelial growth factor expression. Neuroendocrinology. vol 80. issue 5. 2005-04-01. PMID:15677882. |
dopamine agonists reverse lactotrope hyperplasia and hyperprolactinemia and also reduce the pituitary vip content in hyperestrogenized rats. |
2005-04-01 |
2023-08-12 |
rat |
| Oscar Gómez, José Antonio Bals. Implication of pituitary vasoactive intestinal peptide in dopaminergic inhibition of estrogen-induced pituitary hyperplasia and vascular endothelial growth factor expression. Neuroendocrinology. vol 80. issue 5. 2005-04-01. PMID:15677882. |
on the other hand, the dopamine agonists inhibit the estrogen-induced hyperprolactinemia by acting through different pathways than those implicated in the proliferative process. |
2005-04-01 |
2023-08-12 |
rat |
| Karen K Mille. Management of hyperprolactinemia in patients receiving antipsychotics. CNS spectrums. vol 9. issue 8 Suppl 7. 2004-12-07. PMID:15303078. |
when treatment is indicated, specifically when hyperprolactinemia results in amenorrhea in women or testosterone deficiency in men, dopamine agonist therapy is generally not advisable. |
2004-12-07 |
2023-08-12 |
Not clear |
| Ana B F Emiliano, Julie L Fudg. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 29. issue 5. 2004-05-25. PMID:14997175. |
while the classic mechanism of antipsychotic-induced hyperprolactinemia directly involves dopamine cells in the tuberoinfundibular pathway, ssris may act on this system indirectly through gabaergic neurons. |
2004-05-25 |
2023-08-12 |
Not clear |
| Henri Wallaschofski, Martin Eigenthaler, Markus Kiefer, Manfred Donné, Betina Hentschel, Herman J Gertz, Tobias Lohman. Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. Journal of clinical psychopharmacology. vol 23. issue 5. 2004-01-30. PMID:14520125. |
most antipsychotic drugs act as dopamine antagonists, and some of them cause hyperprolactinemia. |
2004-01-30 |
2023-08-12 |
human |
| K C Horner, Y Cazal. Stress in hearing and balance in Meniere's disease. Noise & health. vol 5. issue 20. 2003-11-10. PMID:14558890. |
a further study on non-operated ménière's patients presenting hyperprolactinemia and on dopamine agonist treatment, is needed in order to assess the role of stress in ménière's patients. |
2003-11-10 |
2023-08-12 |
Not clear |
| Christof Schöfl, Beate Schöfl-Siegert, Johann Hinrich Karstens, Michael Bremer, Thomas Lenarz, Jose Sebastian Fernandez Cuarezma, Madjid Samii, Alexander von zur Mühlen, Georg Braban. Falsely low serum prolactin in two cases of invasive macroprolactinoma. Pituitary. vol 5. issue 4. 2003-11-07. PMID:14558675. |
hydrocortisone was substituted and dopamine agonist therapy was started because of moderate hyperprolactinemia. |
2003-11-07 |
2023-08-12 |
Not clear |
| Omar Serri, Constance L Chik, Ehud Ur, Shereen Ezza. Diagnosis and management of hyperprolactinemia. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. vol 169. issue 6. 2003-10-30. PMID:12975226. |
we describe the diagnostic approach and management of hyperprolactinemia in various clinical settings, with emphasis on newer diagnostic strategies and the role of various therapeutic options, including treatment with selective dopamine agonists. |
2003-10-30 |
2023-08-12 |
Not clear |
| J M Goldstei. Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs of today (Barcelona, Spain : 1998). vol 35. issue 3. 2003-10-24. PMID:12973385. |
quetiapine also has minimal activity on dopamine receptors in the tuberoinfundibular dopamine system, thereby avoiding the problem of hyperprolactinemia, common with the standard antipsychotics and some atypical antipsychotics. |
2003-10-24 |
2023-08-12 |
Not clear |
| Brandon J Bankowski, Howard A Zacu. Dopamine agonist therapy for hyperprolactinemia. Clinical obstetrics and gynecology. vol 46. issue 2. 2003-09-22. PMID:12808385. |
dopamine agonist therapy for hyperprolactinemia. |
2003-09-22 |
2023-08-12 |
Not clear |
| Yasuhiko Yamada, Naoko Irizuki, Risa Takayanagi, Koujirou Yamamoto, Yasufumi Sawada, Tatsuji Ig. [Pharmacokinetic/pharmacodynamic analysis of anti-hyperprolactinemic effect of terguride based on dopamine D2 receptor occupancy]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. vol 123. issue 4. 2003-06-18. PMID:12704865. |
terguride has been widely used for the treatment of hyperprolactinemia via partial agonistic action on dopamine d2 receptors in the pituitary. |
2003-06-18 |
2023-08-12 |
Not clear |